Mechanisms of resistance to topoisomerases poisons

被引:9
作者
Prost, S
机构
来源
GENERAL PHARMACOLOGY | 1995年 / 26卷 / 08期
关键词
topoisomerase; drug resistance; cancer treatment;
D O I
10.1016/0306-3623(95)00108-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. Drug resistance remains a major obstacle to cancer treatment. Resistance to chemotherapy can be intrinsic, characterised by the nonresponsiveness of the tumour to the initial treatment. Alternatively, cancers that initially respond to chemotherapy can relapse after various times because of acquired resistance. 2. Resistance to drugs used as single agents is generally accompanied by the development of resistance to other drugs that can be structurally and functionally different. 3. Among the drugs commonly used in cancer treatment there are compounds that have been shown to inhibit DNA topoisomerases (Topos). These critical enzymes regulate the topological conformation of the DNA and participate in essential cellular processes. 4. This paper reviews the Topos' cellular functions, their catalytic activities and the mechanisms of resistance to inhibitors of Topos, with particular attention to the atypical multidrug resistance phenotype.
引用
收藏
页码:1773 / 1784
页数:12
相关论文
共 88 条
[1]  
ALSERN J, 1992, J BIOL CHEM, V267, P12408
[2]   CHARACTERIZATION OF A MAMMALIAN MUTANT WITH A CAMPTOTHECIN-RESISTANT DNA TOPOISOMERASE-I [J].
ANDOH, T ;
ISHII, K ;
SUZUKI, Y ;
IKEGAMI, Y ;
KUSUNOKI, Y ;
TAKEMOTO, Y ;
OKADA, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (16) :5565-5569
[3]   ISOLATION AND CHARACTERIZATION OF A HUMAN CDNA CLONE ENCODING A NOVEL DNA TOPOISOMERASE-II HOMOLOG FROM HELA-CELLS [J].
AUSTIN, CA ;
FISHER, LM .
FEBS LETTERS, 1990, 266 (1-2) :115-117
[4]   CELL-DEATH IN HEALTH AND DISEASE - THE BIOLOGY AND REGULATION OF APOPTOSIS [J].
BELLAMY, COC ;
MALCOMSON, RDG ;
HARRISON, DJ ;
WYLLIE, AH .
SEMINARS IN CANCER BIOLOGY, 1995, 6 (01) :3-16
[5]  
BJORNSTI MA, 1989, CANCER RES, V49, P6318
[6]   SURAMIN IS AN INHIBITOR OF DNA TOPOISOMERASE-II INVITRO AND IN CHINESE-HAMSTER FIBROSARCOMA CELLS [J].
BOJANOWSKI, K ;
LELIEVRE, S ;
MARKOVITS, J ;
COUPRIE, J ;
JACQUEMINSABLON, A ;
LARSEN, AK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (07) :3025-3029
[7]   INHIBITION OF TYPE-II TOPOISOMERASE BY FOSTRIECIN [J].
BORITZKI, TJ ;
WOLFARD, TS ;
BESSERER, JA ;
JACKSON, RC ;
FRY, DW .
BIOCHEMICAL PHARMACOLOGY, 1988, 37 (21) :4063-4068
[8]  
BOURHIS J, 1989, CANCER RES, V49, P5062
[9]   EXPRESSION OF A MUTANT-DNA TOPOISOMERASE-II IN CCRF-CEM HUMAN LEUKEMIC-CELLS SELECTED FOR RESISTANCE TO TENIPOSIDE [J].
BUGG, BY ;
DANKS, MK ;
BECK, WT ;
SUTTLE, DP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (17) :7654-7658
[10]   A NOVEL MUTANT TOPOISOMERASE II-ALPHA PRESENT IN VP-16-RESISTANT HUMAN-MELANOMA CELL-LINES HAS A DELETION OF ALANINE-429 [J].
CAMPAIN, JA ;
GOTTESMAN, MM ;
PASTAN, I .
BIOCHEMISTRY, 1994, 33 (37) :11327-11332